Research & Development

Research Collaborators
Mark-Rosenfeld-2

MARK J. ROSENFELD, M.S., Ph.D

Chief Executive Officer & Chief Science Officer

US Scientist, Joint United Nations FAO/IAEA Committee on Transboundary Diseases (innovated a device for the molecular detection of bird flu and other influenzas)

Visiting Scholar, Giant Panda Conservation and Research Center, Peking University, China

Faculty, Molecular Biology, University of Utah School of Medicine

Consultant, Cannabis Legalization and Regulatory Affairs to Multiple States

Nissim-1

NISSIM GARTI, M.S., Ph.D.

Scientific & Technical Research Partner

Director, Casali Institute of Applied Chemistry, The Hebrew University of Jerusalem

Search Committee, 2013 Nobel Prize in Chemistry

Recipient 2016 Herjie Award (global award for nanotechnology research excellence)

The Japanese Award for the Promotion of Senior Foreign Scientists

Ratner Chair of Chemistry of the Hebrew University

02-personnel-perry-Fine

PERRY G. FINE, M.D.

Medical Director

President Emeritus, American Academy of Pain Medicine

Member, FDA Advisory Board for Opioids

Chair, National Initiative on Pain Control

Board of Directors, American Academy of Pain Medicine

Board of Directors, American Pain Foundation

Consultant, Cannabis Legalization and Regulatory Affairs to Multiple States

02-personnel-jocobi-atsmon

Jacobi (Kobi) Atsmon MD

Clinical Trials Director

Managing Director, Early Phase Clinical Trials, Clinical Research Center (CRC), Tel Aviv Sourasky Medical Center, Israel

Principal Investigator for over 300 clinical studies and considered one of the leading experts in Israel on early phase clinical trials

Senior Lecturer, Tel Aviv University School of Medicine

02-personnel-susan-alpert

SUSAN ALPERT, M.D., Ph.D.

Regulatory Affairs & Clinical Trials Advisor

Director, USFDA Office of Device Evaluation

Senior Vice President − Global Regulatory Affairs,Medtronic

Vice President − Regulatory Sciences, C.R. Baird, Inc.

Chairman, Regulatory Affairs Professionals Society

Advisory Board, Medical Technology Leadership Forum

Executive Committee, Clinical Trials Transformation Initiative

02-personnel-mark-cohen

MARK M. COHEN, MBBS (Hons), PhD, FAMAC, FICAE

Wellness & Sports Medicine

Chairman, Wellness Program,, Royal Melbourne Institute of Technology (RMIT University), Australia

Director, Centre for Complementary Medicine, Institute for Health Services Research, Monash University, Australia

Expert Advisor, Australia Therapeutics Good Authority Complementary Medicine Evaluation Committee

02-personnel-michael-dor

Michael Dor MD, MPA

Medical Advisor – Cannabinoids

Medical Director, Medical Cannabis Unit, Israel Health Ministry

Recipient, Presidential Award (highest Israel civilian honor)

Head, Hospitals Division, Israel Health Ministry

Head, General Medicine Division, Israel Health Ministry

Deputy Director, Health Management, Israel Health Ministry

02-personnel-silviu-brill

Silviu Brill MD

Phase 2 Clinical Director – Neuropathic Pain

Director, Pain Center, Tel Aviv Sourasky Medical Center

Professor, Faculty of Medicine, Ben Gurion University

President Emeritus, Israel Pain Association

President Emeritus, Pain Section, Israel Society of Anesthesiology

Member, European Pain Federation Task Force on Cannabis Based Medicine

02-personnel-david-moody

DAVID E. MOODY, PhD

Cannabinoid Analytics – Bioassays

Chairman, Pharmacology and Toxicology Department, School of Pharmacy, University of Utah

Inspector. National Laboratory Certification Program

Developed and implemented the cannabinoid tests for bodily fluids used by the USFDA, US Drug Enforcement Agency and National Institute of Drug Abuse

Grant Reviewer, Neuropharmacology, NIH Center for Review

COLLABORATIONS & PARTNERSHIPS


Hebrew University of Jerusalem

Kennedy Institute of Rheumatology Oxford University

Great Britain

University of Utah

United States of America

Ben Gurion University of the Negev Israel

Tel Aviv Sourasky Medical Center Israel